Current concepts of radiation treatment of carcinoma in situ of the testis

World J Urol. 1994;12(3):125-30. doi: 10.1007/BF00192268.

Abstract

During a recent international workshop on carcinoma in situ and cancer of the testis held in November 1992, there was consensus about the management of the contralateral testis in patients with unilateral testicular cancer [20]. Such men should be offered a biopsy of the contralateral testis. This consensus was based on (1) the high prevalence of carcinoma in situ (CIS) in the contralateral testis found not only in Danish men but also in studies from other countries and (2) the possibility of eradicating the CIS and thereby preventing the development of invasive cancer by means of localized irradiation with preservation of testosterone production in the testis. The aim of this paper is to outline the present status of the radiation treatment of CIS of the testis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Biopsy
  • Carcinoma in Situ / drug therapy
  • Carcinoma in Situ / epidemiology
  • Carcinoma in Situ / radiotherapy*
  • Carcinoma in Situ / secondary
  • Cell Transformation, Neoplastic / radiation effects*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Follow-Up Studies
  • Humans
  • Incidence
  • Leydig Cells / radiation effects*
  • Male
  • Radiotherapy Dosage
  • Risk Factors
  • Testicular Neoplasms / drug therapy
  • Testicular Neoplasms / epidemiology
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / radiotherapy*
  • Testis / pathology
  • Treatment Outcome

Substances

  • Cisplatin